BelgiumTuberculosis profile
Population  2016 11 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.042 (0.041–0.043) 0.37 (0.36–0.38)
Mortality (HIV+TB only) 0.014 (<0.01–0.019) 0.12 (0.08–0.17)
Incidence  (includes HIV+TB) 1.1 (0.97–1.3) 10 (8.5–12)
Incidence (HIV+TB only) 0.089 (0.073–0.11) 0.78 (0.64–0.93)
Incidence (MDR/RR-TB)** 0.024 (<0.01–0.04) 0.21 (0.08–0.35)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.051 (0.043–0.059) 0.33 (0.28–0.38) 0.38 (0.32–0.44)
Males 0.053 (0.045–0.061) 0.7 (0.59–0.8) 0.75 (0.64–0.87)
Total 0.1 (0.089–0.12) 1 (0.88–1.2) 1.1 (0.97–1.3)
TB case notifications, 2016  
Total cases notified 1 047
Total new and relapse 986
          - % tested with rapid diagnostics at time of diagnosis 48%
          - % with known HIV status 45%
          - % pulmonary 68%
          - % bacteriologically confirmed among pulmonary 87%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.05 (0.04–0.06)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 32 7%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  16
(6–26)
Estimated % of TB cases with MDR/RR-TB 1.6% (0.66–3.3) 8.8% (1.9–24)  
% notified tested for rifampicin resistance 57% 72% 769
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 12, XDR-TB: 3
Patients started on treatment **** MDR/RR-TB: 9, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 79% 905
Previously treated cases, excluding relapse, registered in 2015 73% 55
HIV-positive TB cases registered in 2015 72% 29
MDR/RR-TB cases started on second-line treatment in 2014 50% 12
XDR-TB cases started on second-line treatment in 2014 100% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data